Efficiency of Photodynamic Therapy in the Treatment of Diffuse Facial Viral Warts in an Immunosuppressed Patient: Towards a Gold Standard?

M. Caucanas    P. Gillard    O. Vanhooteghem

Department of Dermatology, Sainte Elisabeth Hospital, Namur, Belgium

Key Words
Photodynamic therapy · Facial viral warts · Immunosuppressed 5-aminolevulinic acid · Papilloma virus · Organ transplant

Abstract
A 64-year-old man with a pulmonary transplant developed diffuse verrucae vulgares of the neck. After the failure of multiple cryotherapy treatments, 3 sessions of photodynamic therapy resulted in rapid therapeutic clinical success. This moderately painful and well-tolerated treatment is reproducible and can be very useful in treating papillomavirus infections in the immunosuppressed patient.

Case Report
We report the case of a 64-year-old man, who had been under immunosuppressive treatment for many years after a pulmonary transplant, who presented with diffuse viral warts on the neck and chin that had been present for 11 months (fig. 1). Cryotherapy sessions were conducted over the course of 9 months without success but with increasing intolerance to the related pain. Imiquimod had not been suggested due to its theoretical contraindications relating to the risk of a graft rejection and a graft-versus-host disease.

A photodynamic therapy (PDT) test session was carried out on the most prominent warts in the submental region, with a very clear improvement after 1 week (fig. 2). Two more sessions were conducted within a 10-day interval, using 2 fields of light each time, thus covering the entire surface of the neck (right and left sides). Three hours after an application of 5-aminolevulinic acid (Metvix®) under an occlusive and opaque dressing, a red light of 634 nm was delivered, with a 37 J/cm² light intensity for the duration of 9 min. A spray bottle filled with spring water, in combination with an integrated cooling fan, was used to decrease pain during illumination. Treatment was relatively well tolerated. The painful sensation lasted 1–2 h after illumination, whereas erythema and swelling decreased after 2–3 days. Side effects were well tolerated and were considered minor by the patient. Complete healing was achieved after 8 days.
A fast and marked improvement was noted after only 2 sessions of PDT. A third session resulted in complete clearance (fig. 3). No recurrence was noted 1 year after the last session of treatment.

Discussion

Viral wart treatments include local keratolytic application, topical retinoids, cryotherapy, intralesional injection of bleomycin, imiquimod, laser CO₂, pulsed dye laser and intralesional immunotherapy [1]. The benefit-risk ratio in organ-transplanted patients is currently being evaluated [2]. PDT has proven to be successful in the treatment of actinic keratosis and basocellular carcinoma. At present, new indications are emerging, including verrucae vulgares.

Several studies show that protoporphyrin IX accumulation after 5-aminolevulinic acid application is not specific to tumour cells [3]. HPV-infected cells also accumulate protoporphyrin IX in a specific manner, as compared to the surrounding healthy cells [4, 5], as demonstrated by in vivo fluorescence spectroscopy [6]. PDT therapeutic effects are due to anti-inflammatory and anti-proliferative properties activated through the release of cytotoxic radicals that destroy keratinocytes via selective apoptosis [7].

Numerous clinical studies have demonstrated the efficiency of PDT in the treatment of viral warts of the hands [8] and feet, (recalcitrant [9–13] or not), including periungual warts. Several studies have shown that PDT is efficient in treating plane warts [14, 15], including those on the face [16]. Ohtsuki et al. [17] treated verrucae vulgares on the hands and feet with a clear clinical improvement in 68.3% of the patients. This improvement was confirmed by a placebo-controlled study led by Bastuji-Garin et al. [18]. In addition, Wang et al. [19] successfully treated 42% of recalcitrant viral warts, and Chong and Kang [20] reported complete healing of recalcitrant foot verrucae vulgares after only 3 PDT sessions. Schroeter et al. [21] treated periungual warts with full clinical success in 90% of patients after a mean of 4.7 sessions. Some authors suggested the use of a keratolytic pre-treatment (urea 10%, salicylic acid 10%, for 1 week) to enhance the treatment’s efficiency, with complete healing in 75% of viral warts [6]. In the immunosuppressed subject, Granel-Brocard et al. [22] reported the therapeutic effect of PDT on recalcitrant warts.

The advantages of PDT are numerous. It is a safe, noninvasive technique, which yields effective therapeutic results in multiple series of patients [17, 23]. The risk of secondary infection after PDT is insignificant, and the cosmetic results are excellent [7]. The technique is particularly interesting in slow-healing subjects and acts selectively, allowing healthy surrounding skin to remain intact and functional [24]. The use of one or several fields of light enables treatment of many lesions at the same time, thus limiting the risk of wart spread and recurrence between sessions. The drawbacks are pain and local side effects such as erythema and swelling, which is generally mild and well tolerated (table 1, table 2, table 3).

Immunosuppressed patients often present with extensive viral warts. Controlling the spread of these warts is of great importance because they can potentially be a source of neoplasia [25]. Our case report shows that PDT can be very efficient in the treatment of verrucae vulgares in immunosuppressed organ-transplanted patients. The technique is easy to implement, resulting in minimal side effects and reproducible results.
We think that PDT should be considered as a gold standard in the treatment of facial verrucae vulgares in immunodepressed patients.

Disclosure

All authors certify that they have no conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject of this manuscript.

Table 1. Efficiency of PDT: patient characteristics, treatment and localisation

| Study      | Patients | Age (years) | Sex | Treatments | Immunologic status | Level of evidence | Localisation |
|------------|----------|-------------|-----|------------|--------------------|-------------------|--------------|
| Lu [15]    | 18       | 18–41       | 13  | 5          | RPW                | NS                | D 1          |
| Ohtsuki [17]| 6        | 22–45       | 2   | 4          | RVV                | NS                | D 2, 3       |
| Morton [24] | 12       | 20–45       | 8   | 4          | RVV                | NS                | D 4          |
| Lin [16]   | 3        | 15–25       | 2   | 1          | RPW                | NS                | D 1          |
| Granel-Brocard [22] | 1 | 54 | 1 | 0 | RVV   | ID                | D 3          |
| Wang [19]  | 12       | 18–70       | 2   | 10         | RVV                | IC                | D 2, 3       |
| Schroeter [21] | 20 | 10–55      | 17  | 3          | RVV, NPT           | NS                | D 4          |
| Schroeter [12] | 31 | 6–74        | 18  | 13         | RVV                | NS                | D 3          |
| Mizuki [14] | 1        | 13          | 0   | 1          | RPW                | NS                | D 1          |
| Fabbrocini [6] | 67    | 18–40       | 31  | 36         | RVV                | NS                | C 3          |
| Stender [9] | 45       | 20–84       | 26  | 19         | RVV                | IC                | C 2, 3       |
| Stender [13] | 30       | 22–74       | 16  | 14         | RVV                | 3 ID              | D 2, 3       |
| Stender [10] | 52       | 16–79       | 42  | 20         | RVV, RPW           | 5 ID              | D 1, 2, 3, 5 |
| Smetana [5] | 1        | NS          | NS  | NS         | NS                 | ID                | D 2          |
| Stender [11] | 4        | NS          | NS  | NS         | RVV                | NS                | D 2, 3, 6, 7 |
| Ammann [23] | 6        | 21–31       | 2   | 4          | RVV                | NS                | D 2          |

F = Female; M = male; NS = not specified; RVV = recalcitrant verrucae vulgares; RPW = recalcitrant plane warts; ID = immunodeficient; IC = immunocompetent; NPT = no previous treatment. 1 = Face; 2 = hand; 3 = foot; 4 = periungual; 5 = arm; 6 = knee; 7 = heel. *First author [reference].
### Table 2. Efficiency of PDT: session specifics

| Studya | Photosensitizer | Occlusion (h) | Session (n) | Interval |
|--------|-----------------|---------------|-------------|----------|
| Lu [15] | ALA 10%         | 4             | 2–3         | 2 w      |
| Ohtsuki [17] | ALA 20%         | 5             | 10          | 2–3 w    |
| Lin [16] | ALA 20%         | 3             | 4–5         | 1 w      |
| Granel-Brocard [22] | MAL      | 3–4           | 5           | 2 m      |
| Wang [19] | ALA 20%         | 4             | 4           | 2 w      |
| Schroeter [21] | ALA 20%         | 3–6           | 2           | 2 w      |
| Schroeter [12] | ALA 20%         | 4             | 4           | 1–7 NS   |
| Mizuki [14] | ALA 20%         | 6             | 2           | NS       |
| Fabbrocini [6] | ALA 20% versus PLC | 5             | 3           | 1 w      |
| Stender [9] | ALA 20% versus PLC | 4             | 6           | 1–2 w    |
| Stender [13] | ALA 20%         | 5             | 1–3         | 10 d     |
| Stender [10] | ALA 20%         | 4–5           | 3           | 1 w      |
| Smetana [5] | ALA 20%         | 4             | 1           |          |
| Stender [11] | ALA 20%         | 12            | 2–3         | NS       |
| Ammann [23] | ALA 20%         | 5–6           | 1           |          |

MAL = Methyl-aminolevulinic; ALA = aminolevulinic acid; PLC = placebo cream; w = week; m = month; d = day. a First author [reference].

### Table 3. Efficiency of PDT: response to treatment

| Studya | Light source | Cure rate | Follow-up |
|--------|--------------|-----------|-----------|
| Lu [15] | Laser 635 nm | CR: 17 persons | 6 m |
| Ohtsuki [17] | RL 633 nm | PR: 68.3% | 4 w |
| Lin [16] | RL 633 nm | CR: 100% | 1–3 m |
| Granel-Brocard [22] | RL 570–670 nm | CR: 100% | 5 m |
| Wang [19] | RL 590–700 nm | CR: 5 persons | 8–16 m |
| Schroeter [21] | RL 580–720 nm | CR: 90% | 5.9 m |
| Schroeter [12] | RL 580–720 nm | CR: 88% | 3 m |
| Mizuki [14] | Metal Halide Lamp 630–700 nm | CR: 100% | 5 m |
| Fabbrocini [6] | Tungsten lamp, 630 nm | CR: 75% under ALA-PDT; 22.8% under PLC-PDT | 22 m |
| Stender [9] | RL 590–700 nm | CR: 100% under ALA-PDT; 71% under PLC-PDT | 18 w |
| Stender [13] | Halogen lamp | CR: 73% | 12 m |
| Stender [10] | White light from slide projector | CR: 58%; ID: 1 person | 3–17 m |
| Smetana [5] | Xenon lamp, RL 590–700 nm | Dramatic clearance | 2 y |
| Stender [11] | Unfiltered lamp | CR: 100% | 6 w to 1 y |
| Ammann [23] | Visible light from slide projector | CR: 1 person | 2 m |

PDL = Pulsed dye laser; CR = complete response; PR = partial response; RL = red light; IPL = intense pulsed light; NS = not specified; MoW = mosaic warts; MyW = myrmecia warts; VIS = visible light; wIRA = waterfiltered infrared A; ALA = aminolevulinic acid; PLC = placebo cream; ID = immunodeficient; m = months; w = weeks; y = years. a First author [reference].
Fig. 1. Viral warts of the neck in a pulmonary transplanted patient under immunosuppressive treatment.

Fig. 2. Clinical image after healing of the test area.
Fig. 3. Complete healing of the warts after three sessions of PDT.

References

1. Bacelieri R, Johnson SM: Cutaneous warts: an evidence-based approach to therapy. Am Fam Physician 2005;72:647–652.
2. Schmook T, Nindl I, Ulrich C, Meyer T, Sterry W, Stockfleth E: Viral warts in organ transplant recipients: new aspects in therapy. Br J Dermatol 2003;149(suppl 66):20–24.
3. Ibbotson SH: Topical 5-aminolaevulinic acid photodynamic therapy for the treatment of skin conditions other than non-melanoma skin cancer. Br J Dermatol 2002;146:178–188.
4. Szeimies RM, Landthaler M, Karrer SJ: Non-oncologic indications for ALA-PDT. Dermatolog Treat 2002;13(suppl 1):S13–S18.
5. Smetana Z, Malik Z, Orenstein A, Mendelson E, Ben-Hur E: Treatment of viral infections with 5-aminolevulinic acid and light. Lasers Surg Med 1997;21:351–358.
6. Fabbrocini G, Di Costanzo MP, Riccardo AM, Quarto M, Colasanti A, Roberti G, Monfrecola G: Photodynamic therapy with topical delta-aminolaevulinic acid for the treatment of plantar warts. J Photochem Photobiol B 2001;61:30–34.
7. Rossi R, Bruscinio N, Riccieri F, Grazzini M, Dindelli M, Lotti T: Photodynamic treatment for viral infections of the skin. G Ital Dermatol Venereol 2009;144:79–83.
8. Kalil CL, Salenave PR, Cignachi S: Hand warts successfully treated with topical 5-aminolevulinic acid and intense pulsed light. Eur J Dermatol 2008;18:207–208.
9. Stender IM, Na R, Fogy H, Gluud C, Wulf HC: Photodynamic therapy with 5-aminolevulinic acid or placebo for recalcitrant foot and hand warts: randomised double-blind trial. Lancet 2000;355:963–966.
10. Stender IM, Wulf HC: Photodynamic therapy of recalcitrant warts with 5-aminolevulinic acid: a retrospective analysis. Acta Derm Venereol 1999;79:400–401.
11. Stender IM, Wulf HC: Treatment of recalcitrant verrucae by photodynamic therapy with topical application of delta-aminolevulinic acid. Clin Exp Dermatol 1996;21:390.
12. Schroeter CA, Pleunis J, van Nispen tot Pannerden C, Reineke T, Neumann HA: Photodynamic therapy: new treatment for therapy-resistant plantar warts. Dermatol Surg 2005;31:71–75.
13. Stender IM, Lock-Andersen J, Wulf HC: Recalcitrant hand and foot warts successfully treated with photodynamic therapy with topical 5-aminolevulinic acid: a pilot study. Clin Exp Dermatol 1999;24:154–159.
14. Mizuki D, Kaneko T, Hanada K: Successful treatment of topical photodynamic therapy using 5-aminolevulinic acid for plane warts. Br J Dermatol 2003;149:1087–1088.
15. Lu YG, Wu JJ, He Y, Yang HZ, Yang YD: Efficacy of topical aminolevulinic acid photodynamic therapy for the treatment of verruca planae. Photomed Laser Surg 2010;28:561–563.
16 Lin MY, Xiang LH: Topical 5-aminolevulinic acid photodynamic therapy for recalcitrant facial flat wart in Chinese subjects. J Dermatol 2008;35:658–661.
17 Ohtsuki A, Hasegawa T, Hirasawa Y, Tsuchihashi H, Ikeda S: Photodynamic therapy using light-emitting diodes for the treatment of viral warts. J Dermatol 2009;36:525–528.
18 Bastuji-Garin S, Laurent R, Basset-Seguin N, Bédane C, Combemale P, Dubertret L: Photodynamic therapy with 5-aminolevulinic acid or placebo for recalcitrant foot and hand warts: randomised double-blind trial (article in French). Ann Dermatol Venereol 2001;128(10 Pt 1):1110–1113.
19 Wang YS, Tay YK, Kwock C, Tan E: Photodynamic therapy with 20% aminolevulinic acid for the treatment of recalcitrant viral warts in an Asian population. Int J Dermatol 2007;46:1180–1184.
20 Chong WS, Kang GY: Dramatic clearance of a recalcitrant acral viral wart using methyl aminolevulinate-red light photodynamic therapy. Photodermatol Photoimmunol Photomed 2009;25:225–226.
21 Schroeter CA, Kaas L, Waterval JJ, Bos PM, Neumann HA: Successful treatment of periungual warts using photodynamic therapy: a pilot study. J Eur Acad Dermatol Venereol 2007;21:1170–1174.
22 Granel-Brocard F, Cuny JF, Schmutz JL: Efficacy of photodynamic therapy (PDT) in a recalcitrant wart in an immunodeficient subject. Eur J Dermatol 2008;18:601.
23 Ammann R, Hunziker T, Braathen LR: Topical photodynamic therapy in verrucae. A pilot study. Dermatology 1995;191:346–347.
24 Morton CA: Topical photodynamic therapy in dermatology. S Afr Med J 2001;91:634–637.
25 Nindl I, Gottschling M, Stockfleth E: Human papillomaviruses and non-melanoma skin cancer: basic virology and clinical manifestations. Dis Markers 2007;23:247–259.